REFERENCES
(1)
Narayanan V. Tuberous sclerosis complex: genetics to pathogenesis.
Pediatr Neurol 2003 Nov;29(5):404-409.
(2) Rumsey N, Clarke A, White P. Exploring the psychosocial concerns of
outpatients with disfiguring conditions. J Wound Care 2003
Jul;12(7):247-252.
(3) Zweegers J, van der Vleuten CJ. The psychosocial impact of an
infantile haemangioma on children and their parents. Arch Dis Child 2012
Oct;97(10):922-926.
(4) Biondo G, Greco S, Mavilia L, Mercuri SR. Treatment of nodular
facial angiofibromas in tuberous sclerosis, using ultrapulse carbon
dioxide laser. Clin Exp Dermatol 2014 Aug;39(6):738-740.
(5) Balestri R, Neri I, Patrizi A, Angileri L, Ricci L, Magnano M.
Analysis of current data on the use of topical rapamycin in the
treatment of facial angiofibromas in tuberous sclerosis complex. J Eur
Acad Dermatol Venereol 2015 Jan;29(1):14-20.
(6) Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner A, et
al. Topical rapamycin therapy to alleviate the cutaneous manifestations
of tuberous sclerosis complex: a double-blind, randomized, controlled
trial to evaluate the safety and efficacy of topically applied
rapamycin. Drugs R D 2012 Sep 1;12(3):121-126.
(7) Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S,
Yamamoto K, et al. Efficacy and Safety of Topical Sirolimus Therapy for
Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized
Clinical Trial. JAMA Dermatol 2017 Jan 1;153(1):39-48.
(8) Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, et
al. Efficacy and Safety of Topical Rapamycin in Patients With Facial
Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT
Randomized Clinical Trial. JAMA Dermatol 2018 Jul 1;154(7):773-780.
(9) Chen PL, Hong JB, Shen LJ, Chen YT, Wang SJ, Liao YH. The efficacy
and safety of topical rapamycin-calcitriol for facial angiofibromas in
patients with tuberous sclerosis complex: a prospective, double-blind,
randomized clinical trial. Br J Dermatol 2020 Oct;183(4):655-663.
(10) Bougueon G, Lagarce F, Martin L, Pailhories H, Bastiat G, Vrignaud
S. Formulation and characterization of a 0.1% rapamycin cream for the
treatment of Tuberous Sclerosis Complex-related angiofibromas. Int J
Pharm 2016 Jul 25;509(1-2):279-284.
(11) Le Guyader G, Vieillard V, Andrieux K, Rollo M, Thirion O,
Wolkenstein P, et al. Long-term stability of 0.1% rapamycin hydrophilic
gel in the treatment of facial angiofibromas. Eur J Hosp Pharm 2020
Mar;27(e1):e48-e52.
(12) Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. Application of
response surface methodology in development of sirolimus liposomes
prepared by thin film hydration technique. Bioimpacts 2013;3(2):75-81.
(13) Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. The effects of
lyophilization on the physico-chemical stability of sirolimus liposomes.
Adv Pharm Bull 2013;3(1):25-29.
(14) Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, Ruano J,
Galan-Gutierrez M, Velez A, et al. Sustained clinical effectiveness and
favorable safety profile of topical sirolimus for tuberous sclerosis -
associated facial angiofibroma. J Eur Acad Dermatol Venereol 2012
Oct;26(10):1315-1318.
(15) Tiedemann Svendsen M, Bygum A, Hansen LK, Broesby-Olsen S. Facial
angiofibromas associated to tuberous sclerosis treated with topical
sirolimus. Ugeskr Laeger 2013 Oct 21;175(43):2569-2570.
(16) Ministry of Health, Consumption and Social Welfare. Madrid, Spain.
Royal Decree 175/2001, of 23 February, which approves the standards of
correct preparation and quality control of magistral formulas
and officinal preparations. Available at:https://www.boe.es/buscar/pdf/2001/BOE-A-2001-5185-consolidado.pdf.
(17) Ministry of Health, Consumption and Social Welfare. Madrid, Spain.
Guide to Good Practice of Preparation of Medications in Hospital
Pharmacy Services. June, 2014. Available at:https://www.mscbs.gob.es/profesionales/farmacia/pdf/GuiaBPP3.pdf.
(18) International Conference on Harmonisation. Validation of Analytical
Procedures: Text and Methodology, 2015, 6–12. .
(19) Ministry of Health, Consumption and Social Welfare, by mandate of
Law 29/2006, of July 26, on guarantee and rational use of medicines and
health products. National Drug Formulary. Madrid, Spain. 2019.;
Available at:https://www.boe.es/biblioteca_juridica/abrir_pdf.php?id=PUB-NT-2019-112.
(20) Yoon HY, Chang IH, Goo YT, Kim CH, Kang TH, Kim SY, et al.
Intravesical delivery of rapamycin via folate-modified liposomes
dispersed in thermo-reversible hydrogel. Int J Nanomedicine 2019 Aug
5;14:6249-6268.
(21) Park J, Yun SK, Cho YS, Song KH, Kim HU. Treatment of angiofibromas
in tuberous sclerosis complex: the effect of topical rapamycin and
concomitant laser therapy. Dermatology 2014;228(1):37-41.
(22) Onyesom I, Lamprou DA, Sygellou L, Owusu-Ware SK, Antonijevic M,
Chowdhry BZ, et al. Sirolimus encapsulated liposomes for cancer therapy:
physicochemical and mechanical characterization of sirolimus
distribution within liposome bilayers. Mol Pharm 2013 Nov
4;10(11):4281-4293.
(23) Rouf MA, Vural I, Renoir JM, Hincal AA. Development and
characterization of liposomal formulations for rapamycin delivery and
investigation of their antiproliferative effect on MCF7 cells. J
Liposome Res 2009;19(4):322-331.
(24) Valizadeh H, Ghanbarzadeh S, Zakeri-Milani P. Fusogenic liposomal
formulation of sirolimus: improvement of drug anti-proliferative effect
on human T-cells. Drug Dev Ind Pharm 2015;41(9):1558-1565.
(25) Department of Health and Human Services. Centers for Disease
Control and Prevention National Institute for Occupational Safety and
Health. NIOSH List of Antineoplastic and Other Hazardous Drugs in
Healthcare Settings, 2014. Available
in: https://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf.
2014; . Accessed 19/06, 2019.
(26) Cortell Fuster C, Martínez Gómez MA, Cercós Lleti AC, Climente
Martí M. Topical rapamycin in the treatment of facial angiofibromas in
tuberous sclerosis: a systematic review based on evidence. J Dermatolog
Treat 2021 Apr 6:1-7.